LNAI
Lunai Bioworks Inc.
Biotechnology
Market Cap$8M
5Y Perf.-31.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
LNAI vs CDNA
Revenue, margins, valuation, and 5-year total return — side by side.
CDNA
CareDx, Inc
Medical - Diagnostics & Research
Market Cap$1.11B
5Y Perf.-22.7%
LNAI vs CDNA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | LNAI | CDNA |
|---|---|---|
| Industry | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $8M | $1.11B |
| Revenue (TTM) | $0.00 | $413M |
| Net Income (TTM) | $-126M | $-8M |
| Gross Margin | — | 48.2% |
| Operating Margin | — | -3.3% |
| Forward P/E | — | 22.8x |
| Total Debt | $10M | $20M |
| Cash & Equiv. | $93K | $65M |
Quick Verdict: LNAI vs CDNA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CDNA leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. Lunai Bioworks Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
LNAI
Lunai Bioworks Inc.
The Income Pick
LNAI is the clearest fit if your priority is income & stability and growth exposure.
- beta 0.79
- EPS growth -18.5%
- Lower volatility, beta 0.79, current ratio 0.04x
Best for: income & stability and growth exposure
CDNA
CareDx, Inc
The Long-Run Compounder
CDNA carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 385.1% 10Y total return vs LNAI's -85.4%
- -2.0% margin vs LNAI's -7.4%
- +45.2% vs LNAI's -85.4%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | LNAI | 21.7% revenue growth vs CDNA's 13.8% |
| Quality / Margins | CDNA | -2.0% margin vs LNAI's -7.4% |
| Stability / Safety | LNAI | Beta 0.79 vs CDNA's 1.39 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CDNA | +45.2% vs LNAI's -85.4% |
| Efficiency (ROA) | CDNA | -1.9% ROA vs LNAI's -18.8%, ROIC -5.7% vs -22.4% |
LNAI vs CDNA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
LNAI vs CDNA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCDNALAGGINGLNAI
LNAILunai Bioworks Inc.
0leads
CDNACareDx, Inc
4leads
6 Total Categories
CATEGORYLEADERvs LNAIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CDNA1/1
Valuation MetricsMultiples, price ratios, and targets
CDNA1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CDNA6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
CDNA6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CDNA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CDNA and LNAI operate at a comparable scale, with $413M and $0 in trailing revenue.
| Metric | LNAILunai Bioworks In… | CDNACareDx, Inc |
|---|---|---|
| RevenueTrailing 12 months | $0 | $413M |
| EBITDAEarnings before interest/tax | -$12M | $2M |
| Net IncomeAfter-tax profit | -$126M | -$8M |
| Free Cash FlowCash after capex | -$6M | $65M |
| Gross MarginGross profit ÷ Revenue | — | +48.2% |
| Operating MarginEBIT ÷ Revenue | — | -3.3% |
| Net MarginNet income ÷ Revenue | — | -2.0% |
| FCF MarginFCF ÷ Revenue | — | +15.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +39.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +80.8% | +126.3% |
CDNA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
CDNA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | LNAILunai Bioworks In… | CDNACareDx, Inc |
|---|---|---|
| Market CapShares × price | $8M | $1.1B |
| Enterprise ValueMkt cap + debt − cash | $18M | $1.1B |
| Trailing P/EPrice ÷ TTM EPS | -0.03x | -53.60x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 22.85x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 2.92x |
| Price / BookPrice ÷ Book value/share | — | 3.77x |
| Price / FCFMarket cap ÷ FCF | — | 30.66x |
CDNA leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
CDNA leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
CDNA delivers a -2.6% return on equity — every $100 of shareholder capital generates $-3 in annual profit, vs $-3 for LNAI. On the Piotroski fundamental quality scale (0–9), CDNA scores 5/9 vs LNAI's 1/9, reflecting solid financial health.
| Metric | LNAILunai Bioworks In… | CDNACareDx, Inc |
|---|---|---|
| ROE (TTM)Return on equity | -3.2% | -2.6% |
| ROA (TTM)Return on assets | -18.8% | -1.9% |
| ROICReturn on invested capital | -22.4% | -5.7% |
| ROCEReturn on capital employed | -33.2% | -5.8% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 5 |
| Debt / EquityFinancial leverage | — | 0.06x |
| Net DebtTotal debt minus cash | $10M | -$46M |
| Cash & Equiv.Liquid assets | $92,700 | $65M |
| Total DebtShort + long-term debt | $10M | $20M |
| Interest CoverageEBIT ÷ Interest expense | -11.70x | — |
CDNA leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
CDNA leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CDNA five years ago would be worth $2,759 today (with dividends reinvested), compared to $1,461 for LNAI. Over the past 12 months, CDNA leads with a +45.2% total return vs LNAI's -85.4%. The 3-year compound annual growth rate (CAGR) favors CDNA at 37.7% vs LNAI's -47.3% — a key indicator of consistent wealth creation.
| Metric | LNAILunai Bioworks In… | CDNACareDx, Inc |
|---|---|---|
| YTD ReturnYear-to-date | -65.7% | +12.0% |
| 1-Year ReturnPast 12 months | -85.4% | +45.2% |
| 3-Year ReturnCumulative with dividends | -85.4% | +161.1% |
| 5-Year ReturnCumulative with dividends | -85.4% | -72.4% |
| 10-Year ReturnCumulative with dividends | -85.4% | +385.1% |
| CAGR (3Y)Annualised 3-year return | -47.3% | +37.7% |
CDNA leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — LNAI and CDNA each lead in 1 of 2 comparable metrics.
Risk & Volatility
LNAI is the less volatile stock with a 0.79 beta — it tends to amplify market swings less than CDNA's 1.39 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CDNA currently trades 92.3% from its 52-week high vs LNAI's 13.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | LNAILunai Bioworks In… | CDNACareDx, Inc |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.79x | 1.39x |
| 52-Week HighHighest price in past year | $2.45 | $23.24 |
| 52-Week LowLowest price in past year | $0.15 | $10.96 |
| % of 52W HighCurrent price vs 52-week peak | +13.6% | +92.3% |
| RSI (14)Momentum oscillator 0–100 | 43.6 | 56.4 |
| Avg Volume (50D)Average daily shares traded | 25.9M | 667K |
Evenly matched — LNAI and CDNA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | LNAILunai Bioworks In… | CDNACareDx, Inc |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $24.00 |
| # AnalystsCovering analysts | — | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +7.9% |
Insufficient data to determine a leader in this category.
Key Takeaway
CDNA leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallCareDx, Inc (CDNA)Leads 4 of 6 categories
Loading custom metrics...
LNAI vs CDNA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is LNAI or CDNA a better buy right now?
Analysts rate CareDx, Inc (CDNA) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — LNAI or CDNA?
Over the past 5 years, CareDx, Inc (CDNA) delivered a total return of -72.
4%, compared to -85. 4% for Lunai Bioworks Inc. (LNAI). Over 10 years, the gap is even starker: CDNA returned +385. 1% versus LNAI's -85. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — LNAI or CDNA?
By beta (market sensitivity over 5 years), Lunai Bioworks Inc.
(LNAI) is the lower-risk stock at 0. 79β versus CareDx, Inc's 1. 39β — meaning CDNA is approximately 76% more volatile than LNAI relative to the S&P 500.
04Which is growing faster — LNAI or CDNA?
On earnings-per-share growth, the picture is similar: Lunai Bioworks Inc.
grew EPS -18. 5% year-over-year, compared to -143. 0% for CareDx, Inc. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — LNAI or CDNA?
Lunai Bioworks Inc.
(LNAI) is the more profitable company, earning 0. 0% net margin versus -5. 6% for CareDx, Inc — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNAI leads at 0. 0% versus -5. 5% for CDNA. At the gross margin level — before operating expenses — CDNA leads at 67. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — LNAI or CDNA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is LNAI or CDNA better for a retirement portfolio?
For long-horizon retirement investors, Lunai Bioworks Inc.
(LNAI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 79)). Both have compounded well over 10 years (LNAI: -85. 4%, CDNA: +385. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between LNAI and CDNA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.